Amphotericin B-resistant yeast infection in severely immunocompromised patients
- PMID: 3284339
- DOI: 10.1016/0002-9343(88)90059-9
Amphotericin B-resistant yeast infection in severely immunocompromised patients
Abstract
Systemic yeast infections are a major cause of morbidity and mortality in severely immunocompromised patients. The in vitro susceptibility to amphotericin B of 29 yeasts causing fungemia was examined in 26 patients undergoing allogeneic or autologous bone marrow transplantation and/or myelosuppressive chemotherapy. The minimal inhibitory concentrations (MICs) of amphotericin B observed with blood isolates from these patients were significantly higher than those observed with blood, sputum, or skin isolates from non-immunocompromised patients (p less than 0.01). All episodes (10 of 10) of bloodstream infection in immunocompromised patients caused by isolates with MICs greater than 0.8 micrograms/ml were fatal, versus eight of 17 episodes of bloodstream infection caused by yeasts with MICs of 0.8 micrograms/ml or less (p = 0.04). Although 15 of 26 patients received empiric treatment with amphotericin B before laboratory evidence of fungemia developed, the amphotericin B susceptibilities of their isolates were not significantly different from those of patients who had not received empiric amphotericin B treatment. It is concluded that yeast fungemia in severely immunocompromised patients is often caused by organisms resistant to the usual concentrations of amphotericin B obtainable in vivo, and that this finding is clinically significant.
Similar articles
-
Do in vitro susceptibility data predict the microbiologic response to amphotericin B? Results of a prospective study of patients with Candida fungemia.J Infect Dis. 1998 Feb;177(2):425-30. doi: 10.1086/514193. J Infect Dis. 1998. PMID: 9466531
-
Candida rugosa in immunocompromised infection. Case reports, drug susceptibility, and review of the literature.Cancer. 1985 Jul 15;56(2):318-20. doi: 10.1002/1097-0142(19850715)56:2<318::aid-cncr2820560219>3.0.co;2-4. Cancer. 1985. PMID: 3859361
-
Candida and candidaemia. Susceptibility and epidemiology.Dan Med J. 2013 Nov;60(11):B4698. Dan Med J. 2013. PMID: 24192246 Review.
-
Candidemia in women with breast carcinoma treated with high-dose chemotherapy and autologous bone marrow transplantation.Cancer. 2003 Jul 1;98(1):24-30. doi: 10.1002/cncr.11470. Cancer. 2003. PMID: 12833451
-
The use of fluconazole prophylaxis in patients with chemotherapy-induced neutropenia.Leuk Lymphoma. 1992 Nov;8(4-5):353-9. doi: 10.3109/10428199209051014. Leuk Lymphoma. 1992. PMID: 1290959 Review.
Cited by
-
Diagnosis and Treatment Challenges of Candida guilliermondii in Immunocompromised Patients: A Case Study in a Neutropenic AML Patient.Case Rep Infect Dis. 2024 Jul 22;2024:7806235. doi: 10.1155/2024/7806235. eCollection 2024. Case Rep Infect Dis. 2024. PMID: 39077031 Free PMC article.
-
Topical polyene antifungals in hematopoietic cell transplant patients: tolerability and efficacy.Support Care Cancer. 2004 Jul;12(7):517-25. doi: 10.1007/s00520-004-0634-1. Epub 2004 Apr 24. Support Care Cancer. 2004. PMID: 15108100 Clinical Trial.
-
Patterns of amphotericin B killing kinetics against seven Candida species.Antimicrob Agents Chemother. 2004 Jul;48(7):2477-82. doi: 10.1128/AAC.48.7.2477-2482.2004. Antimicrob Agents Chemother. 2004. PMID: 15215097 Free PMC article.
-
Strain delineation and epidemiology of Candida (Clavispora) lusitaniae.J Clin Microbiol. 1992 Feb;30(2):449-54. doi: 10.1128/jcm.30.2.449-454.1992. J Clin Microbiol. 1992. PMID: 1537915 Free PMC article.
-
In vitro activity of A-192411.29, a novel antifungal lipopeptide.Antimicrob Agents Chemother. 2000 May;44(5):1242-6. doi: 10.1128/AAC.44.5.1242-1246.2000. Antimicrob Agents Chemother. 2000. PMID: 10770758 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical